RxDoctor Payments Data

Neil Kao, MD

Allergy · Greenville, SCNPI 1720089477

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $18,990 of the $22,698 with a category attached, or 83.7%. It is spread thinly across 40 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations.

$22,698in general payments, 2019–2025

Across 841 payments — averaging $26.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5K
  • Sanofi$2K
  • GSK$2K
  • Novartis$2K
  • Alk-abello, Inc$2K
  • CSL Behring$1K
  • plus $9K from 34 others
$1,679,016in research payments, 2019–2025

Across 948 payments — averaging $1771.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$666K
  • Sanofi$257K
  • Merck$202K
  • Novartis$160K
  • Genentech, Inc.$91K
  • Regeneron$88K
  • plus $215K from 7 others

What the payments were for

  • Travel & lodging$3,69916%
  • Food & beverage$18,99084%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$373,808
Medicare patients
548
Services billed
18,774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab39$97,279
PanzygaImmun Glob G(Igg)-Ifas/Glycine22$84,885
Breo ElliptaFluticasone/Vilanterol78$39,442
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$30,699
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$19,968
Arnuity ElliptaFluticasone Furoate45$14,899
Epinephrine77$11,618
SymbicortBudesonide/Formoterol Fumarate33$11,119
Qvar RedihalerBeclomethasone Dipropionate25$10,322
Fluticasone-SalmeterolFluticasone Propion/Salmeterol51$9,584
Wixela InhubFluticasone Propion/Salmeterol58$7,816
Advair HfaFluticasone Propion/Salmeterol17$6,822
Albuterol Sulfate HfaAlbuterol Sulfate243$6,681
Incruse ElliptaUmeclidinium Bromide11$5,785
DuleraMometasone/Formoterol22$5,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech, Inc.Xolair$27$97,27939 claims
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta, Incruse Ellipta$1,630$90,825165 claims
PfizerPanzyga$1,101$84,88522 claims
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$5,072$34,28164 claims
Hikma Pharmaceuticals USAEpinephrine$182$11,61877 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$126$10,32225 claims
MerckDulera$1,054$5,66822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other allergy in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →